Cepheid Corporation

Roche Molecular Systems, Inc.

Hoffmann-la Roche Inc.

Roche Diagnostics Gmbh

F. Hoffmann-la Roche Ag

Russell G Higuchi

Alexander A Gall

Thomas W Myers

David H Gelfand

Henry A Erlich

Sergey G Lokhov

Edwin Wei-Lung Lai

Stacey Ellen Wallace

Cherie Holcomb

Andrew Kohlway

Leena McCann

Kriszten Kocmond

Alice M Wang

Reuel Van Atta

Gary A Peltz

Edward Soh Smith

Jia Li

Nancy Jeneane Schönbrunner

Edwin W Lai

Reuel Vanatta

Carita Maria Elfstrom

Sunhee Kwon Ro

Bonnie Fijal

Chris Lykke

Leena Mccann

Compositions and methods for detecting bladder cancer are provided. In some embodiments, methods of monitoring recurrence of bladder cancer are provided. In some embodiments, the methods comprise detecting a set of markers consisting of CRH, IGF2, KRT20, and ANXA10.

Methods of detecting bladder cancer

Described herein are methods and compositions that provide highly efficient nucleic acid amplification. In some embodiments, this allows a 3-fold or greater increase of amplification product for each amplification cycle and therefore increased sensitivity and speed over conventional PCR. Modified bases can be employed in primers to provide this base-3 or greater amplification with satisfactory PCR cycle times, which are improved, as compared to those observed in the absence of modified bases.

Exponential base-3 and greater nucleic acid amplification with reduced amplification time

Compositions and methods for detecting bladder cancer are provided. In some embodiments, methods of detecting low grade bladder cancer are provided. In some embodiments, methods of monitoring recurrence of bladder cancer are provided. In some embodiments, the methods comprise detecting androgen receptor (AR) and/or uroplakin 1B (UPK1B).

Described herein are methods and compositions that provide highly efficient nucleic acid amplification. In some embodiments, this allows a greater than 2-fold increase of amplification product for each amplification cycle and therefore increased sensitivity and speed over conventional PCR.

Exponential base-greater-than-2 nucleic acid amplification

In various embodiments methods of determining methylation of DNA are provided. In one illustrative, but non-limiting embodiment the method comprises i) contacting a biological sample comprising a nucleic acid to a first matrix material comprising a first column or filter where said matrix material binds and/or filters nucleic acids in said sample and thereby purifies the DNA; ii) eluting the bound DNA from the first matrix material and denaturing the DNA to produce eluted denatured DNA; iii) heating the eluted DNA in the presence of bisulfite ions to produce a deaminated nucleic acid; iv) contacting said deaminated nucleic acid to a second matrix material comprising a second column to bind said deaminated nucleic acid to said second matrix material; v) desulfonating the bound deaminated nucleic acid and/or simultaneously eluting and desulfonating the nucleic acid by contacting the deaminated nucleic acid with an alkaline solution to produce a bisulfite converted nucleic acid; vi) eluting said bisulfite converted nucleic acid from said second matrix material; and vii) performing methylation specific PCR and/or nucleic acid sequencing, and/or high resolution melting analysis (HRM) on said bisulfite-converted nucleic acid to determine the methylation of said nucleic acid, wherein at least steps iv) through vi) are performed in a single reaction cartridge.

Integrated purification and measurement of DNA methylation and co-measurement of mutations and/or MRNA expression levels in an automated reaction cartridge

Methods of determining methylation of DNA are provided. In one illustrative, but non-limiting embodiment the method comprises i) contacting a biological sample comprising a nucleic acid to a first matrix material comprising a first column or filter where said matrix material binds and/or filters nucleic acids in said sample and thereby purifies the DNA; ii) eluting the bound DNA from the first matrix material and denaturing the DNA to produce eluted denatured DNA; iii) heating the eluted DNA in the presence of bisulfite ions to produce a deaminated nucleic acid; iv) contacting said deaminated nucleic acid to a second matrix material comprising a second column to bind said deaminated nucleic acid to said second matrix material; v) desulphonating the bound deaminated nucleic acid and/or simultaneously eluting and desulphonating the nucleic acid by contacting the deaminated nucleic acid with an alkaline solution to produce a bisulfite converted nucleic acid; vi) eluting said bisulfite converted nucleic acid from said second matrix material; and vii) performing methylation specific PCR and/or nucleic acid sequencing, and/or high resolution melting analysis (HRM) on said bisulfite-converted nucleic acid to determine the methylation of said nucleic acid, wherein at least steps iv) through vi) are performed in a single reaction cartridge.

Integrated purification and measurement of DNA methylation and co-measurement of mutations and/or mRNA expression levels in an automated reaction cartridge

Compositions and methods for detecting markers associated with bladder cancer

The present invention relates to the materials and methods for the identification of methylated nucleotides in samples of genomic DNA. The present invention also relates to methods of diagnosis of specific conditions by identification of specific methylated nucleotides.

Methods of identification of methylation of CpG

The invention is a single-tube multiplex assay, capable of simultaneously amplifying, detecting and quantifying multiple nucleic acid targets, using multiple hybridization probes, labeled with the same fluorescent reporter label, but each having a distinct melting temperature. The assay can be further multiplexed with the use of multiple sets of hybridization probes, each set labeled with a separate fluorescent reporter label.

Multiplex quantitative nucleic acid amplification and melting assay

The present invention provides methods of detecting cancer cells by detecting the quantity of SENP1 and/or telomerase in a sample.

SENP1 as a marker for cancer

The present invention relates to polymorphisms of the FRZB gene and the analysis of nucleic acids thereof. The invention further relates to methods of predicting risks of certain conditions in individual and kits for the determination of such risks.

Associations of polymorphisms in the FRZB gene in obesity and osteoporosis

Growing community of inventors

San Francisco, CA, United States of America

Russell G Higuchi